Brigatinib: First Global Approval.

Article Details

Citation

Markham A

Brigatinib: First Global Approval.

Drugs. 2017 Jul;77(10):1131-1135. doi: 10.1007/s40265-017-0776-3.

PubMed ID
28597393 [ View in PubMed
]
Abstract

Brigatinib (ALUNBRIG) is a small molecule antineoplastic anaplastic lymphoma kinase (ALK) inhibitor being developed by ARIAD Pharmaceuticals (a wholly-owned subsidiary of Takeda Pharmaceutical Company). In April 2017 brigatinib received accelerated approval in the USA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. The development of resistance to crizotinib is a therapeutic challenge that has led to the development of second-generation ALK-inhibitors such as brigatinib, which have activity against treatment-resistant ALK mutants. This article summarizes the milestones in the development of brigatinib leading to this first global approval for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
BrigatinibALK tyrosine kinase receptorProteinHumans
Yes
Inhibitor
Details
BrigatinibEpidermal growth factor receptorProteinHumans
Yes
Inhibitor
Details
BrigatinibInsulin-like growth factor 1 receptorProteinHumans
Unknown
Inhibitor
Details
BrigatinibReceptor-type tyrosine-protein kinase FLT3ProteinHumans
Unknown
Inhibitor
Details
BrigatinibTyrosine-protein kinase ABL1ProteinHumans
Unknown
Inhibitor
Details
Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
BrigatinibCytochrome P450 2C8ProteinHumans
No
Substrate
Details
BrigatinibCytochrome P450 3A4ProteinHumans
No
Substrate
Details
Drug Reactions
Reaction
Details